Abstract:Doxorubicin exposure in INS‐1 cells led to decreased insulin signaling, elevated ALDH2 degradation, and induced ceramide‐mediated mitochondrial dysfunction. The ALDH2 agonist ALDA1 effectively mitigated these effects. ALDH2 activation could serve as a therapeutic target for the precise treatment of chemotherapy‐induced β‐cell dysfunction. Aims The aim of this study was to better understand how the chemotherapy drug doxorubicin contributes to the development of β‐cell dysfunction and to explore its relationship with mitochondrial aldehyde dehydrogenase‐2 (ALDH2). Materials and Methods In order to investigate this hypothesis, doxorubicin was administered to INS‐1 cells, a rat insulinoma cell line, either with or without several target protein activators and inhibitors. ALDH2 activity was detected with a commercial kit and protein levels were determined with western blot. Mitochondrial ROS, membrane potential, and lipid ROS were determined by commercial fluorescent probes. The cell viability was measured by CCK‐assay. Results Exposure of INS‐1 cells to doxorubicin decreased active insulin signaling resulting in elevated ALDH2 degradation, compared with control cells by the induction of acid sphingomyelinase mediated ceramide induction. Further, ceramide induction potentiated doxorubicin induced mitochondrial dysfunction. Treatment with the ALDH2 agonist, ALDA1, blocked doxorubicin‐induced acid sphingomyelinase activation which significantly blocked ceramide induction and mitochondrial dysfunction mediated cell death. Treatment with the ALDH2 agonist, ALDA1, stimulated casein kinase‐2 (CK2) mediated insulin signaling activation. CK2 silencing neutralized the function of ALDH2 in the doxorubicin treated INS‐1 cells. Conclusions Mitochondrial ALDH2 activation could inhibit the progression of doxorubicin induced pancreatic β‐cell dysfunction by inhibiting the acid sphingomyelinase induction of ceramide, by regulating the activation of CK2 signaling. Our research lays the foundation of ALDH2 activation as a therapeutic target for the precise treatment of chemotherapy drug induced β‐cell dysfunction.

Diabetogenic agent alloxan is a proteasome inhibitor

Hepatic Glucokinase Activity is the Primary Defect in Alloxan-Induced Diabetes of Mice

The protective effect of Alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose

The Analysis of Ultrastructure and Gene Expression of Sarco/endoplasmic Reticulum Calcium Handling Proteins in Alloxan-Induced Diabetic Rat Myocardium.

Acetylcholinesterase is Associated with Apoptosis in Β Cells and Contributes to Insulin-Dependent Diabetes Mellitus Pathogenesis

The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas

Proteasomal Degradation of WT Proinsulin in Pancreatic Beta Cells.

Allicin Alleviates Diabetes Mellitus by Inhibiting the Formation of Advanced Glycation End Products

Diabetic Model Induced by Alloxan in Mice and Its Affecting Factors

Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme

In vitro and in vivo protective effect of Ganoderma lucidum polysaccharides on alloxan-induced pancreatic islets damage.

Xuezhikang (Eeuroe",A(0)Center Dot) Reduced Renal Cell Apoptosis In Streptozocin-Induced Diabetic Rats Through Regulation Of Bcl-2 Family

Molecular Mechanisms of Toxicity and Cell Damage by Chemicals in a Human Pancreatic Beta Cell Line, 1.1B4

Down-Regulation of Brain-Pancreas Relative Protein in Diabetic Rats and by High Glucose in PC12 Cells: Prevention by Calpain Inhibitors

The protective roles of allicin on type 1 diabetes mellitus through AMPK/mTOR mediated autophagy pathway

Intracellular Toxic Advanced Glycation End-Products in 1.4E7 Cell Line Induce Death with Reduction of Microtubule-Associated Protein 1 Light Chain 3 and p62

Mitochondrial ALDH2 improves ß‐cell survival and function against doxorubicin‐induced apoptosis by targeting CK2 signaling

Inhibition of the Keap1/Nrf2 Signaling Pathway Significantly Promotes the Progression of Type 1 Diabetes Mellitus

Berberine Ameliorates Hyperglycemia In Alloxan-Induced Diabetic C57bl/6 Mice Through Activation Of Akt Signaling Pathway

Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury.

Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection.